• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Stallergenes S.A. (GENP) - Financial and Strategic SWOT Analysis Review

  • ID: 1315564
  • May 2015
  • 46 pages
  • GlobalData

FEATURED COMPANIES

  • BioAlliance Pharma SA
  • Ipsen S.A.
  • NicOx SA
  • Novagali Pharma SA
  • sanofi-aventis AB
  • Vetoquinol S A
  • MORE

Stallergenes S.A. (GENP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by The publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • BioAlliance Pharma SA
  • Ipsen S.A.
  • NicOx SA
  • Novagali Pharma SA
  • sanofi-aventis AB
  • Vetoquinol S A
  • MORE

List of Tables
List of Figures
Section 1 - About the Company
Stallergenes S.A. - Key Facts
Stallergenes S.A. - Key Employees
Stallergenes S.A. - Key Employee Biographies
Stallergenes S.A. - Major Products and Services
Stallergenes S.A. - Pharmaceutical Pipeline Products Data
Stallergenes S.A., Pipeline Products by Therapy Area
Stallergenes S.A., Pipeline Products by Development Phase
Stallergenes S.A. - History
Stallergenes S.A. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 - Company Analysis
Stallergenes S.A. - Business Description
Stallergenes S.A. - Corporate Strategy
Stallergenes S.A. - SWOT Analysis
SWOT Analysis - Overview
Stallergenes S.A. - Strengths
Strength - Broad Portfolio of Products
Strength - Strong Financial Performance
Strength - Strong In-house Research Capabilities
Stallergenes S.A. - Weaknesses
Weakness - Geographical Concentration: Europe
Stallergenes S.A. - Opportunities
Opportunity - Rising Geriatric Population
Opportunity - Joining G5 Health
Opportunity - Strategic Expansions
Stallergenes S.A. - Threats
Threat - Cost Containment Pressures
Threat - Uncertain R&D Outcomes
Threat - Intense Competition
Stallergenes S.A. - Key Competitors
Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Stallergenes S.A., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Stallergenes S.A., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015
Stallergenes S.A., Recent Deals Summary
Section 5 - Company’s Recent Developments
Apr 21, 2015: Strong Sales Growth In Q1 2015 (up 7.5%) Exceeding Targets
Mar 03, 2015: 2.5% growth in net sales & EBITA outperformed 2014 targets
Oct 24, 2014: Stallergenes Continues Its International Expansion With The Opening Of An Affiliate In Canada
Oct 23, 2014: Stallergenes sales reach €45.7 million in Q3 2014; Oralair achieves market leadership in France; Continued expansion of international markets (up 33%)
Jul 24, 2014: Stallergenes Half-Year Revenues And Results
Mar 05, 2014: Appointment of Christian Chavy as Chief Executive Officer of Stallergenes
Section 6 - Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
Stallergenes S.A., Key Facts
Stallergenes S.A., Key Employees
Stallergenes S.A., Key Employee Biographies
Stallergenes S.A., Major Products and Services
Stallergenes S.A., Number of Pipeline Products by Therapy Area
Stallergenes S.A., Number of Pipeline Products by Development Stage
Stallergenes S.A., Pipeline Products By Therapy Area and Development Phase
Stallergenes S.A., History
Stallergenes S.A., Subsidiaries
Stallergenes S.A., Key Competitors
Stallergenes S.A., Ratios based on current share price
Stallergenes S.A., Annual Ratios
Stallergenes S.A., Interim Ratios
Stallergenes S.A., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Stallergenes S.A., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015
Stallergenes S.A., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Stallergenes S.A., Pipeline Products by Therapy Area
Stallergenes S.A., Pipeline Products by Development Phase
Stallergenes S.A., Performance Chart (2010 - 2014)
Stallergenes S.A., Ratio Charts
Stallergenes S.A., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Stallergenes S.A., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015

Note: Product cover images may vary from those shown

Novagali Pharma SA
NicOx SA
Vetoquinol S A
Ipsen S.A.
sanofi-aventis AB
BioAlliance Pharma SA

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Grifols, S.A. Takeda Pharmaceutical Company Limited Alexion Pharmaceuticals Teva Pharmaceutical Industries Ltd. Endo International Plc. Essilor International S.A.